Should I buy or sell HLS Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLTRF, but not buy additional shares or sell existing shares. View HLTRF analyst ratings or view top-rated stocks .

What is HLS Therapeutics' stock price target for 2024?

1 brokerages have issued 12 month price targets for HLS Therapeutics' stock. Their HLTRF share price targets range from $28.00 to $36.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 1,066.5% from the stock's current price. View analysts price targets for HLTRF or view top-rated stocks among Wall Street analysts .

How have HLTRF shares performed in 2023?

HLS Therapeutics' stock was trading at $7.25 at the beginning of 2023. Since then, HLTRF stock has decreased by 62.2% and is now trading at $2.7433. View the best growth stocks for 2023 here .

How do I buy shares of HLS Therapeutics?

Shares of HLTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

HLS Therapeutics Stock Price, News & Analysis (OTCMKTS:HLTRF)

$2.74

0.00 (0.00%)

(As of 11/30/2023 ET)

Compare

Today's Range: $2.74
▼
$2.74
50-Day Range: $2.74
▼
$3.84
52-Week Range: $2.60
▼
$7.68

Volume: N/A
Average Volume: 8,255 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.00

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

About HLS Therapeutics Stock (OTCMKTS:HLTRF)

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; Vascepa, an icosapent ethyl capsules for cardiovascular disease; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels. In addition, the company holds the United States marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia, a cardiovascular therapeutic; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

HLTRF Stock Price History

30 days | 90 days | 365 days | Advanced Chart

HLTRF Stock News Headlines

October 26, 2023 | finance.yahoo.com

HLS Therapeutics to Host Q3 Fiscal 2023 Financial Results Conference Call

September 6, 2023 | finance.yahoo.com

HLS Therapeutics to Present at H.C. Wainwright's 25th Annual Global Investment Conference

December 1, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

August 10, 2023 | finance.yahoo.com

HLS Therapeutics Announces Q2 Fiscal 2023 Financial Results

June 8, 2023 | marketwatch.com

HLS Therapeutics Chairman to Retire; Polar Nominee to Join Board

May 12, 2023 | markets.businessinsider.com

HLS Therapeutics Inc (HLS) Receives a Buy from Clarus

May 3, 2023 | finance.yahoo.com

HLS Therapeutics to Host Q1 Fiscal 2023 Financial Results Conference Call

April 21, 2023 | finance.yahoo.com

HLS Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

December 1, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

April 17, 2023 | marketwatch.com

HLS Therapeutics Appoints Craig Millian CEO to Head Company

March 15, 2023 | markets.businessinsider.com

HLS Therapeutics earnings: here's what Wall Street expects

March 2, 2023 | finance.yahoo.com

HLS Therapeutics to Host Q4 and Fiscal 2022 Financial Results Conference Call

January 12, 2023 | finance.yahoo.com

Shareholders in HLS Therapeutics (TSE:HLS) are in the red if they invested three years ago

January 1, 2023 | finance.yahoo.com

HLS Therapeutics Inc. (HLTRF)

December 14, 2022 | finance.yahoo.com

HLS Therapeutics Inc. (TSE:HLS): When Will It Breakeven?

November 10, 2022 | finance.yahoo.com

HLS Therapeutics Announces Q3 Fiscal 2022 Financial Results and Renewal of Normal Course Issuer Bid

October 5, 2022 | benzinga.com

HLS Therapeutics Stock (OTC:HLTRF), Guidance and Forecast

October 3, 2022 | finance.yahoo.com

HLS Therapeutics Announces Updates to its Credit Agreement

April 28, 2022 | finance.yahoo.com

HLS Therapeutics to Host Q1 Fiscal 2022 Financial Results Conference Call

April 26, 2022 | marketwatch.com

HLS Therapeutics Completes Letter of Intent With Canada Alliance on Vascepa

April 26, 2022 | finance.yahoo.com

HLS Therapeutics completes negotiations with pCPA for Vascepa®

March 14, 2022 | finance.yahoo.com

HLS Therapeutics to Host Q4 & Fiscal 2021 Financial Results Conference Call

January 12, 2022 | finance.yahoo.com

HLS Therapeutics to Present at the Sidoti Investor Conference

November 18, 2021 | apnews.com

Saladax Biomedical and HLS Therapeutics Strengthen Partnership With an Exclusive Distribution Agreement for Canada

November 11, 2021 | finance.yahoo.com

HLS Therapeutics to Present at the Stifel 2021 Virtual Healthcare Conference

November 8, 2021 | finance.yahoo.com

HLS Therapeutics Inc.'s (TSE:HLS) Shift From Loss To Profit

October 4, 2021 | finance.yahoo.com

HLS Therapeutics to Participate in Two Virtual Non-Deal Roadshows

See More Headlines

Receive HLTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for HLS Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Drug Manufacturers - Specialty & Generic
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:HLTRF
CUSIP: N/A
CIK: N/A
Web: www.hlstherapeutics.com
Phone: 647-495-9000
Fax: N/A
Employees: 99
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.00
High Stock Price Target: $36.00
Low Stock Price Target: $28.00
Potential Upside/Downside: +1,066.5%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Mr. Tim Hendrickson M.B.A. (Age 51)
Chief Financial Officer
Comp: $388.8k
Dr. Jason A. Gross Pharm.D. (Age 58)
Vice President of Scientific Affairs
Comp: $260.75k
Mr. Ryan C. Lennox B.A. (Age 42)
J.D., Senior VP of Legal, HR & Compliance and Corporate Secretary
Comp: $286.58k
Mr. Craig Stuart Millian M.B.A. (Age 55)
CEO & Director
Brian T. Walsh
Senior Vice President of Commercial
Mr. David Spence (Age 55)
VP & Corporate Controller

Key Competitors

View All Competitors

HLTRF Stock Analysis - Frequently Asked Questions

Should I buy or sell HLS Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for HLS Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HLTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HLTRF, but not buy additional shares or sell existing shares.
View HLTRF analyst ratings or view top-rated stocks.
What is HLS Therapeutics' stock price target for 2024?: 1 brokerages have issued 12 month price targets for HLS Therapeutics' stock. Their HLTRF share price targets range from $28.00 to $36.00. On average, they anticipate the company's share price to reach $32.00 in the next twelve months. This suggests a possible upside of 1,066.5% from the stock's current price.
View analysts price targets for HLTRF or view top-rated stocks among Wall Street analysts.
How have HLTRF shares performed in 2023?: HLS Therapeutics' stock was trading at $7.25 at the beginning of 2023. Since then, HLTRF stock has decreased by 62.2% and is now trading at $2.7433.
View the best growth stocks for 2023 here.
How do I buy shares of HLS Therapeutics?: Shares of HLTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:HLTRF) was last updated on 12/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial